Top-Rated StocksTop-RatedNASDAQ:NUVL Nuvalent (NUVL) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free NUVL Stock Alerts $65.94 -1.26 (-1.88%) (As of 03:21 PM ET) Add Compare Share Share Today's Range$64.44▼$66.5350-Day Range$62.76▼$88.9952-Week Range$33.03▼$89.39Volume147,024 shsAverage Volume442,885 shsMarket Capitalization$4.22 billionP/E RatioN/ADividend YieldN/APrice Target$90.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Nuvalent alerts: Email Address Nuvalent MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside38.7% Upside$90.78 Price TargetShort InterestBearish20.97% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 7 Articles This WeekInsider TradingSelling Shares$80.64 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.89) to ($3.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.27 out of 5 starsMedical Sector377th out of 907 stocksPharmaceutical Preparations Industry165th out of 422 stocks 4.5 Analyst's Opinion Consensus RatingNuvalent has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNuvalent has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted20.97% of the float of Nuvalent has been sold short.Short Interest Ratio / Days to CoverNuvalent has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.Change versus previous monthShort interest in Nuvalent has recently increased by 6.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuvalent does not currently pay a dividend.Dividend GrowthNuvalent does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NUVL. Previous Next 1.8 News and Social Media Coverage News SentimentNuvalent has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Nuvalent this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for NUVL on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Nuvalent to their MarketBeat watchlist in the last 30 days. This is a decrease of -90% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nuvalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $80,638,250.00 in company stock.Percentage Held by Insiders14.77% of the stock of Nuvalent is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.26% of the stock of Nuvalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nuvalent are expected to decrease in the coming year, from ($2.89) to ($3.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvalent is -30.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvalent is -30.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvalent has a P/B Ratio of 5.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Nuvalent Stock (NASDAQ:NUVL)Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Read More NUVL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NUVL Stock News HeadlinesApril 25, 2024 | insidertrades.comNuvalent, Inc. (NASDAQ:NUVL) Director Matthew Shair Sells 37,500 SharesApril 25, 2024 | insidertrades.comNuvalent, Inc. (NASDAQ:NUVL) Director Sells $2,386,875.00 in StockApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 11, 2024 | insidertrades.comNuvalent, Inc. (NASDAQ:NUVL) Director Sells $2,566,500.00 in StockApril 7, 2024 | insidertrades.comDeborah Ann Miller Sells 3,000 Shares of Nuvalent, Inc. (NASDAQ:NUVL) StockMarch 30, 2024 | insidertrades.comInsider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells 22,000 Shares of StockMarch 26, 2024 | insidertrades.comNuvalent, Inc. (NASDAQ:NUVL) Insider Darlene Noci Sells 20,000 SharesApril 19, 2024 | americanbankingnews.comNuvalent (NASDAQ:NUVL) Now Covered by Jefferies Financial GroupApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 18, 2024 | investing.comNuvalent director Shair sells over $2.4 million in company stockApril 18, 2024 | msn.comJefferies Initiates Coverage of Nuvalent (NUVL) with Buy RecommendationApril 18, 2024 | msn.comJefferies starts Nuvalent at buy, cites lung cancer drug candidatesApril 17, 2024 | msn.comNuvalent (NUVL) Price Target Increased by 6.08% to 104.19April 16, 2024 | americanbankingnews.comNuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of "Moderate Buy" by AnalystsApril 8, 2024 | finance.yahoo.comNuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024April 7, 2024 | investing.comNuvalent's chief legal officer sells shares worth over $220kApril 5, 2024 | finance.yahoo.comChief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL)March 25, 2024 | finance.yahoo.comChief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL)March 22, 2024 | finance.yahoo.comCompanies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In GrowthMarch 19, 2024 | finance.yahoo.comDirector Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL)March 16, 2024 | finance.yahoo.comNUVL Apr 2024 100.000 callMarch 5, 2024 | prnewswire.comNuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024February 29, 2024 | finance.yahoo.comNuvalent Inc (NUVL) Reports Full Year and Q4 2023 Financial Results with Strong Cash Position ...February 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Arcutis Biotherapeutics (ARQT)February 27, 2024 | benzinga.comRecap: Nuvalent Q4 EarningsFebruary 27, 2024 | finanznachrichten.deNuvalent, Inc.: Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520February 27, 2024 | markets.businessinsider.comNuvalent, Inc. Q4 Loss increases, misses estimatesSee More Headlines Receive NUVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NUVL CUSIPN/A CIK1861560 Webwww.nuvalent.com Phone857-357-7000FaxN/AEmployees92Year FoundedN/APrice Target and Rating Average Stock Price Target$90.78 High Stock Price Target$110.00 Low Stock Price Target$42.00 Potential Upside/Downside+35.1%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-25.74% Return on Assets-24.50% Debt Debt-to-Equity RatioN/A Current Ratio22.83 Quick Ratio22.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.94 per share Price / Book6.14Miscellaneous Outstanding Shares64,070,000Free Float54,605,000Market Cap$4.31 billion OptionableOptionable Beta1.29 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. James R. Porter Ph.D. (Age 48)CEO, President & Director Comp: $998.02kProf. Matthew D. Shair Ph.D. (Age 55)Founder, Head of Scientific Advisory Board & Director Comp: $235kMs. Alex Balcom CPA (Age 39)M.B.A., CFO & Treasurer Comp: $654.22kDr. Christopher D. Turner M.D. (Age 55)Chief Medical Officer Comp: $714.26kDr. Benjamin Lane Ph.D.Senior Vice President of Technical OperationsMs. Deborah Ann Miller J.D. (Age 48)Ph.D., Chief Legal Officer & Secretary Comp: $595.96kMr. Matthew MetivierSenior Vice President of Human ResourcesMs. Darlene Noci (Age 46)Chief Development Officer Mr. Henry Pelish Ph.D.Senior Vice President of Drug DiscoveryMr. John Soglia Ph.D.Senior Vice President of Translational DevelopmentMore ExecutivesKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLAlpine Immune SciencesNASDAQ:ALPNBridgeBio PharmaNASDAQ:BBIOPerrigoNYSE:PRGOAlkermesNASDAQ:ALKSView All CompetitorsInsiders & InstitutionsMatthew ShairSold 37,500 sharesTotal: $2.39 M ($63.65/share)Allspring Global Investments Holdings LLCBought 189 shares on 4/18/2024Ownership: 0.003%Matthew ShairSold 37,500 sharesTotal: $2.46 M ($65.56/share)Renaissance Capital LLCBought 17,327 shares on 4/9/2024Ownership: 0.027%Matthew ShairSold 37,500 sharesTotal: $2.57 M ($68.44/share)View All Insider TransactionsView All Institutional Transactions NUVL Stock Analysis - Frequently Asked Questions Should I buy or sell Nuvalent stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVL shares. View NUVL analyst ratings or view top-rated stocks. What is Nuvalent's stock price target for 2024? 10 brokers have issued 1 year target prices for Nuvalent's shares. Their NUVL share price targets range from $42.00 to $110.00. On average, they anticipate the company's stock price to reach $90.78 in the next twelve months. This suggests a possible upside of 38.7% from the stock's current price. View analysts price targets for NUVL or view top-rated stocks among Wall Street analysts. How have NUVL shares performed in 2024? Nuvalent's stock was trading at $73.59 on January 1st, 2024. Since then, NUVL shares have decreased by 11.1% and is now trading at $65.43. View the best growth stocks for 2024 here. When is Nuvalent's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our NUVL earnings forecast. How were Nuvalent's earnings last quarter? Nuvalent, Inc. (NASDAQ:NUVL) posted its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.02. What ETFs hold Nuvalent's stock? ETFs with the largest weight of Nuvalent (NASDAQ:NUVL) stock in their portfolio include Tema Oncology ETF (CANC), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Invesco DWA SmallCap Momentum ETF (DWAS), Harbor Corporate Culture Small Cap ETF (HAPS), Principal Healthcare Innovators ETF (BTEC), Renaissance IPO ETF (IPO), Invesco Nasdaq Biotechnology ETF (IBBQ) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). When did Nuvalent IPO? Nuvalent (NUVL) raised $151 million in an initial public offering on Thursday, July 29th 2021. The company issued 8,900,000 shares at $16.00-$18.00 per share. Who are Nuvalent's major shareholders? Nuvalent's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Capital LLC (0.03%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Alexandra Balcom, Andrew A F Hack, Anna Protopapas, Christopher Durant Turner, Darlene Noci, Deborah Ann Miller and Matthew Shair. View institutional ownership trends. How do I buy shares of Nuvalent? Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NUVL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
